Physician profile
Surabhi A Atreja
NPI 1528233418
$25,347.89
in general payments reported to CMS, 2019-2025
22 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $157 · 2021: $419 · 2022: $81.28 · 2023: $799 · 2024: $967 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $3,568 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250 · Travel and Lodging: $2,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,750.00 |
| Food and Beverage | $3,567.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
| Travel and Lodging | $2,840.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $21,746.34 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Medtronic Vascular, INC. | $955.53 | 2019 | |
| Medtronic, INC. | $718.31 | 2021-2025 | Symplicity G3, Endurant Iis |
| Philips North America LLC | $419.80 | 2023-2025 | (P84) Igt Devices Systems, Igt Devices Undivided, Igt Devices Systems Undivided |
| Abbott Laboratories | $223.98 | 2023-2025 | Mitraclip, Diamondback Peripheral, Navitor |
| Shockwave Medical, INC | $194.54 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $172.86 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $171.74 | 2019-2022 | |
| Biotronik INC. | $144.33 | 2021-2024 | Orsiro Mission, Recross |
| Abiomed | $144.15 | 2019-2025 | |
| Novo Nordisk INC | $89.17 | 2025 | Wegovy |
| Cardiovascular Systems INC. | $88.31 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $81.47 | 2019 | |
| Edwards Lifesciences Corporation | $45.84 | 2022-2023 | Sapien 3 Ultra Resilia |
| Cordis US Corp. | $30.92 | 2025 | Mynxgrip |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.87 | 2019-2021 | |
| Cardiva Medical, INC. | $17.43 | 2021 | |
| Acarix USA INC. | $15.84 | 2024 | Cadscor System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.82 | 2020 | |
| Amarin Pharma, INC. | $14.67 | 2019 | |
| Boston Scientific Corporation | $13.93 | 2022 | |
| Gilead Sciences, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surabhi Atreja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.